Recombinant CD5L anticorps (PE)

N° du produit ABIN7867170

L’anticorps anti-CD5L Chimeric Lapin est utilisé pour la détection de CD5L dans des échantillons de Humain. Il a été validé pour FACS.

Aperçu rapide pour Recombinant CD5L anticorps (PE) (ABIN7867170)

Antigène: CD5L (CD5 Molecule-Like (CD5L))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Chimeric

Conjugué: Cet anticorp CD5L est conjugé à/à la PE

Application: Flow Cytometry (FACS)

Clone: DMC441

Détail du produit anti-CD5L anticorps (PE)

Fonction: PE-conjugated Anti-CD5L antibody(DMC441), IgG1 Chimeric mAb

Purification: Purified from cell culture supernatant by affinity chromatography

Isotype: IgG1

Information d'application

Indications d'application: Flow Cyt 1:100

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Liquid PBS with 0.05 %  Proclin300, 1 % BSA

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store at 2°C-8°C for 6 months

Date de péremption: 6 months

Détails sur CD5L

Antigène: CD5L (CD5 Molecule-Like (CD5L))

Autre désignation: CD5L

Sujet:

Synonyms: AIM, API6, CT-2, hAIM, PRO229, SP-ALPHA, Spalpha

Target Background: Secreted protein that acts as a key regulator of lipid synthesis: mainly expressed by macrophages in lymphoid and inflamed tissues and regulates mechanisms in inflammatory responses, such as infection or atherosclerosis. Able to inhibit lipid droplet size in adipocytes. Following incorporation into mature adipocytes via CD36-mediated endocytosis, associates with cytosolic FASN, inhibiting fatty acid synthase activity and leading to lipolysis, the degradation of triacylglycerols into glycerol and free fatty acids (FFA). CD5L-induced lipolysis occurs with progression of obesity: participates in obesity-associated inflammation following recruitment of inflammatory macrophages into adipose tissues, a cause of insulin resistance and obesity-related metabolic disease. Regulation of intracellular lipids mediated by CD5L has a direct effect on transcription regulation mediated by nuclear receptors ROR-gamma (RORC). Acts as a key regulator of metabolic switch in T-helper Th17 cells. Regulates the expression of pro-inflammatory genes in Th17 cells by altering the lipid content and limiting synthesis of cholesterol ligand of RORC, the master transcription factor of Th17-cell differentiation. CD5L is mainly present in non-pathogenic Th17 cells, where it decreases the content of polyunsaturated fatty acyls (PUFA), affecting two metabolic proteins MSMO1 and CYP51A1, which synthesize ligands of RORC, limiting RORC activity and expression of pro-inflammatory genes. Participates in obesity-associated autoimmunity via its association with IgM, interfering with the binding of IgM to Fcalpha:mu receptor and enhancing the development of long-lived plasma cells that produce high-affinity IgG autoantibodies (By similarity). Also acts as an inhibitor of apoptosis in macrophages: promotes macrophage survival from the apoptotic effects of oxidized lipids in case of atherosclerosis (PubMed:24295828). Involved in early response to microbial infection against various pathogens by acting as a pattern recognition receptor and by promoting autophagy (PubMed:16030018, PubMed:24223991, PubMed:24583716, PubMed:25713983).